Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Mario Mandalà(Ospedale Papa Giovanni XXIII), Helen Gogas(National and Kapodistrian University of Athens), Ana Arance(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Stéphane Dalle(Hospices Civils de Lyon), C. Lance Cowey(Texas Oncology), Michael Schenker, Jean-Jacques Grob(Hôpital de la Timone), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Marcus O. Butler(Princess Margaret Cancer Centre), Michele Maio(University of Siena), Mark R. Middleton(Churchill Hospital), Luis de la Cruz‐Merino(Hospital Universitario Virgen Macarena), Petr Arenberger(Charles University), Victoria Atkinson(University of Queensland), Andrew Hill(Trans Tasman Radiation Oncology Group), Leslie A. Fecher(University of Michigan–Ann Arbor), Michael Millward(University of Western Australia), Nikhil I. Khushalani(Moffitt Cancer Center), Paola Queirolo(Ospedale Policlinico San Martino), Maurice Lobo(Bristol-Myers Squibb (United States)), Veerle de Pril(Bristol-Myers Squibb (United States)), John T. Loffredo(Bristol-Myers Squibb (United States)), James Larkin(Royal Marsden NHS Foundation Trust), Jeffrey S. Weber(NYU Langone Health)

The Lancet Oncology

September 19, 2020

Cited by 521

Abstract

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al.|New England Journal of Medicine|2017|2.2k

Georgina V. Long, Axel Hauschild, Mario Santinami et al.|New England Journal of Medicine|2017|1.5k